Results 71 to 80 of about 3,471,294 (187)

Progressive in vivo development of resistance to cefiderocol in Pseudomonas aeruginosa

European Journal of Clinical Microbiology & Infectious Diseases, 2022
AbstractWe report in vivo development of cefiderocol (FDC) resistance among four sequential Pseudomonas aeruginosa clinical isolates ST244 recovered from a single patient, without exposure to FDC, which raises concern about the effectiveness of this novel drug. The first recovered P.
Mustafa Sadek, Rémi Le Guern, Eric Kipnis, Philippe Gosset, Laurent Poirel, Rodrigue Dessein, Patrice Nordmann   +6 more
openaire   +3 more sources

Cefiderocol: An Overview of Its in-vitro and in-vivo Activity and Underlying Resistant Mechanisms [PDF]

Frontiers in Medicine, 2021
Treatment of multidrug-resistant (MDR) Gram-negative bacteria (GNB) infections has led to a global public health challenging due to the bacterial resistance and limited choices of antibiotics. Cefiderocol (CFDC), a novel siderophore cephalosporin possessed unique drug delivery systems and stability to β-lactamases, has the potential to become first ...
Jiahui Yao, Jin Wang, Mengli Chen, Yun Cai   +3 more
openaire   +3 more sources

Cefiderocol for the Treatment of Multidrug-Resistant Gram-Negative Bacteria: A Systematic Review of Currently Available Evidence

Frontiers in Pharmacology, 2022
Cefiderocol is a novel synthetic siderophore-conjugated antibiotic that hijacks the bacterial iron transport systems facilitating drug entry into cells, achieving high periplasmic concentrations.
Chuanhai Wang, Deqing Yang, Yifan Wang, Wentao Ni   +3 more
doaj   +1 more source

Adaptive resistance to cefiderocol in carbapenem-resistant Acinetobacter baumannii (CRAB): microbiological and clinical issues

Heliyon, 2023
Abstract Purpose: Determining the best available therapy for carbapenem-resistant Acinetobacter baumannii (CRAB) infections is a challenge. Cefiderocol is an attractive alternative drug effective against many resistance mechanisms in Gram-negative bacteria.
Anissa Desmoulin, Loïk Sababadichetty, Laure Kamus, Marion Daniel, Lucie Feletti, Nicolas Allou, Anaïs Potron, Anne-Gaëlle Leroy, Marie-Christine Jaffar-Bandjee, Olivier Belmonte, Thomas Garrigos, Guillaume Miltgen   +11 more
openaire   +3 more sources

Cefiderocol and Sulbactam-Durlobactam against Carbapenem-Resistant Acinetobacter baumannii

Antibiotics, 2023
Infections caused by carbapenem-resistant Acinetobacter baumannii (CRAB) remain a clinical challenge due to limited treatment options. Recently, cefiderocol, a novel siderophore cephalosporin, and sulbactam-durlobactam, a bactericidal β-lactam–β-lactamase inhibitor combination, have been approved by the Food and Drug Administration for the treatment of
Arta Karruli, Antonella Migliaccio, Spyros Pournaras, Emanuele Durante-Mangoni, Raffaele Zarrilli   +4 more
openaire   +5 more sources

Cefiderocol, a new antibiotic against multidrug-resistant Gram-negative bacteria [PDF]

Revista Española de Quimioterapia, 2021
Cefiderocol is a novel catechol-substituted siderophore cephalosporin that binds to the extracellular free iron, and uses the bacterial active iron transport channels to penetrate in the periplasmic space of Gram-negative bacteria (GNB). Cefiderocol overcomes many resistance mechanisms of these bacteria.
Silva, J T, López-Medrano, F
openaire   +3 more sources

The Burden of the Serious and Difficult-to-Treat Infections and a New Antibiotic Available: Cefiderocol

Frontiers in Pharmacology, 2021
Background: Infection is a disease that can occur due to the entrance of a virus, bacteria, and other infectious agents. Cefiderocol is innovative cephalosporin drug that belongs to a special class of antibiotics, sideromycins, which are taken up by ...
Yasaman Taheri, Yasaman Taheri, Nataša Joković, Jelena Vitorović, Oliver Grundmann, Oliver Grundmann, Alfred Maroyi, Daniela Calina   +7 more
doaj   +1 more source

Positron Emission Tomography Imaging of Bacterial Infections With an Enterobactin Analog to Monitor Treatment Efficacy With a Catechol Antibiotic

Angewandte Chemie, Volume 138, Issue 17, 20 April 2026.
Synopsis. The [68Ga]GaIII‐TREN‐CAM radiochelate selectively accumulates in Gram‐negative sites of infection and noninvasively monitors treatment response a siderophore antibiotic. ABSTRACT Positron emission tomography (PET) is an emerging tool under clinical investigation for the detection of bacterial infections.
M. Andrey Joaqui‐Joaqui, Phuong Nguyen Tran, Axia Marlin, Fiona Armstrong‐Pavlik, Minhua Cao, Valérie C. Pierre, Eszter Boros   +6 more
wiley   +2 more sources

Reduce susceptibility to cefiderocol in gram negative bacteria in children: Is hope already lost before it’s even arrived?

Journal of Infection and Public Health
Background: In last years the diffusion of carbapenem resistance in Gram-negative bacteria (CR-GNB) is increasing worldwide, mainly due to the expression of carbapenemases.
Chiara Russo, Alessio Mesini, Marcello Mariani, Elisa Tavella, Claudia Sette, Elisabetta Ugolotti, Claudia Bartalucci, Candida Palmero, Roberto Bandettini, Elio Castagnola   +9 more
doaj   +1 more source

Cefiderocol for treatment of an empyema due to extensively drug-resistant Pseudomonas aeruginosa: Clinical observations and susceptibility testing considerations

IDCases, 2020
Cefiderocol is a novel siderophore cephalosporin antibacterial with activity against carbapenem-resistant Gram-negative bacteria including Pseudomonas aeruginosa.
Wesley D. Kufel, Jeffrey M. Steele, Scott W. Riddell, Zachary Jones, Pegah Shakeraneh, Timothy P. Endy   +5 more
doaj   +1 more source